Loteprednol 0.25% (Eysuvis) for Dry Eye Disease
Date: May 17, 2021
Issue #:
1624Summary:
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis– Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved for
this indication. Other formulations of loteprednol are
approved for treatment of steroid-responsive ocular
inflammatory conditions, inflammation after ocular
surgery, and seasonal allergic conjunctivitis.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Alrex Cequa Cyclosporine Dry eye disease Eysuvis Inveltys Lacrisert lifitegrast Lotemax loteprednol Restasis Tobramycin Xiidra Zylet Source Type: research
More News: Allergy & Immunology | Conjunctivitis | Corticosteroid Therapy | Drugs & Pharmacology | Opthalmology | Restasis